FDA okays Tris Pharma's liquid non-stimulant drug for paediatric ADHD
30 May 2024
Drug Approval
Tris Pharma announced that the FDA has cleared Ondya XR (clonidine hydrochloride) for paediatric use in attention-deficit hyperactivity disorder (ADHD).
The once-daily extended-release non-stimulant oral suspension, with night-time dosing, is indicated as monotherapy or adjunctive therapy to stimulants for ADHD patients as young as six years old. According to Tris, Ondya XR is the first liquid non-stimulant ADHD product approved in the US. The drug is slated to hit US pharmacies in the second half.
Non-stimulant formulations are crucial for patients who don't respond well to stimulants or experience adverse effects from them. “Securing FDA approval…is not just an important milestone, but a testament to our unwavering commitment to…improving outcomes for this patient population,” remarked Tris CEO Ketan Mehta.
The company noted that Ondya XR’s approval was backed by data from well-controlled studies of clonidine hydrochloride extended-release tablets.
Clonidine was introduced in clinical practice in 1966 as a centrally acting anti-hypertensive agent, and remains a widely-prescribed drug for multiple indications. The extended-release tablet of clonidine hydrochloride marketed as Kapvay by Shionogi was first approved in 2010 for the treatment of ADHD.
Apart from Ondya XR, Tris’ current portfolio of oral extended-release ADHD medications includes Dynavel XR (amphetamine) and Quillivant XR/QuilliChew ER (methylphenidate hydrochloride), which have been developed using the company’s proprietary LiquiXR technology. Tris’ pipeline also has several candidates in development for ADHD, pain, addiction and other neurological disorders.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.